Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesVicapsys Life Sciences Inc

Vicapsys Life Sciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.5 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1400
Market Cap
27.52M

Momentum Score

…

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.20
Low
0.60
High
52 Week Price Range
0.15
Low
1.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.50
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.17
ROE
-1059.16%
Net Debt
0.62M
ROCE
18.21%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.69M -0.99M -1.18M -0.98M -0.77M
Net income -0.69M -0.99M -1.18M -1.67M -0.77M
Selling general administrative - 0.77M 1.03M 0.63M 0.66M
Reconciled depreciation - - 0.00M 0.03M 0.03M
Ebit - -1.05M - -0.98M -0.77M
Ebitda -0.65M -0.90M - -0.27M -0.73M
Depreciation and amortization - 0.03M - 0.71M 0.03M
Operating income -0.65M -0.81M -1.05M -0.98M -0.77M
Other operating expenses 0.65M 0.81M - 0.64M 0.77M
Interest expense 0.04M 0.09M 0.02M 0.68M 0.10M
Tax provision - - 0.00M 0.00M -
Net interest income - - -0.14M - -
Income tax expense - - - 0.68M -0.10M
Total revenue - - 0.00M 0.00M 0.00M
Total operating expenses 0.65M 0.81M 1.05M 0.64M 0.77M
Total other income expense net -0.04M -0.18M - -0.34M 0.10M
Net income from continuing ops - - -1.18M -0.98M -0.24M
Net income applicable to common shares - - - -0.99M -0.24M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.00M 0.01M 0.04M 0.07M 0.40M
Intangible assets - - - - 0.40M
Other current assets - 0.03M - 0.06M 0.01M
Total liab 3.58M 2.89M 1.97M 1.02M 0.85M
Total stockholder equity -3.58M -2.88M -1.93M -0.95M -0.45M
Other current liab 0.12M 0.12M - 0.12M 0.12M
Common stock 0.03M 0.03M - 0.03M 0.02M
Capital stock - - 0.03M 0.03M 0.02M
Retained earnings -17.99M -17.29M -16.30M -15.12M -13.89M
Cash 0.00M 0.01M 0.01M 0.01M 0.00M
Total current liabilities 3.58M 2.89M 1.97M 1.02M 0.85M
Net debt 0.62M 0.57M 0.34M -0.01M -0.00M
Short term debt 0.62M 0.58M - - -
Short long term debt - - 0.35M - -
Short long term debt total 0.62M 0.58M - - -
Other stockholder equity 14.37M 14.37M - 15.09M 13.42M
Total current assets 0.00M 0.01M 0.04M 0.07M 0.00M
Net tangible assets - - - -0.95M -0.49M
Accounts payable 2.84M 2.20M 1.50M 0.91M 0.74M
Non current assets total - - 0.00M 0.00M 0.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - 0.00M 0.10M
Change to liabilities - - - 0.27M -0.14M
Total cashflows from investing activities - - - - 0.10M
Net borrowings - - 0.26M - -
Total cash from financing activities 0.01M 0.12M 0.41M 0.03M 0.56M
Change to operating activities - - - -0.00M -0.01M
Net income -0.69M -0.99M -1.18M -0.98M -0.77M
Change in cash -0.01M 0.00M -0.00M -0.20M -0.26M
Begin period cash flow 0.01M 0.01M 0.01M 0.22M 0.26M
End period cash flow 0.00M 0.01M 0.01M 0.01M 0.00M
Total cash from operating activities -0.02M -0.12M -0.42M -0.24M -0.26M
Issuance of capital stock - - 0.10M 0.00M 0.56M
Depreciation - - 0.00M 0.03M 0.03M
Other cashflows from investing activities - -0.00M - - -
Other cashflows from financing activities - 0.05M - 0.03M 0.10M
Change to netincome - - - 0.45M -0.10M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.66M 0.73M 0.63M 0.27M 0.46M
Stock based compensation - 0.02M 0.02M 0.11M 0.01M
Other non cash items 0.01M 0.14M 0.12M 0.34M -0.10M
Free cash flow -0.02M -0.12M -0.42M -0.24M -0.26M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VICP
Vicapsys Life Sciences Inc		 -
-%		 0.50 - - 0.00 0.03 0.43 -55.20
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Vicapsys Life Sciences Inc

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

7778 Mcginnis Ferry Road, Suwanee, GA, United States, 30024

972 891 8033

https://vicapsys.com

2

Name Title Year Born
Mr. Federico Pier CEO, Exec. Chairman & Interim Pres 1968
Mr. Jeffery Wright CPA, CPA Chief Financial Officer 1983
Dr. Mark C. Poznansky M.D., Ph.D. Chief Scientist Advisor & Founder NA
Mr. Federico Pier CEO, Executive Chairman & Interim President 1968
Mr. Jeffery Wright CPA Chief Financial Officer 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…